{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024177","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.944661+00:00","generated_at":"2026-06-21T23:15:14.389763+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"IN8bio reports Q3 2022 net loss of $7.4M; updates on INB-100 and INB-400 programs","bullets":["Net loss of $7.4M ($0.34/share) for Q3 2022 vs $3.4M ($0.25) in Q3 2021; R&D expenses rose to $4.3M.","Cash of $27.6M as of Sep 30, 2022, down from $37.0M at Dec 31, 2021; raised $9.8M net from equity offering.","INB-100 Phase 1: all three high-risk AML patients show durable morphologic CR >1 year; two >2 years; no DLTs; ASH data planned.","Filed IND for INB-400; partnered with Univ of Louisville for GMP manufacturing for Phase 2 trial.","Appointed Kenneth LaMontagne as SVP Business Development; added Dr. Michael Bishop to Scientific Advisory Board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024177","json":"https://secwatch.observer/filing/0000950170-22-024177.json","markdown":"https://secwatch.observer/filing/0000950170-22-024177.md","text":"https://secwatch.observer/filing/0000950170-22-024177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000095017022024177/0000950170-22-024177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000095017022024177/inab-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:15:14.389763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8515d29d2f2064c83819b5d1467f3ac65c0ba350","claim":"IN8BIO, INC. reported the third quarter ended September 30, 2022 results: revenue $27.6 million, net income $7.4 million, or $0.34 per basic and diluted common share, EPS $0.34 per basic and diluted common share.","evidence_excerpt":"of Louisville as the GMP manufacturing center for INB-400. • Strengthened the balance sheet through an equity offering raising net proceeds of $9.8 million; cash position of $27.6 million as of September 30, 2022. NEW YORK, Nov. 10, 2022 -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000095017022024177/0000950170-22-024177-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$27.6 million"},{"label":"Net income","value":"$7.4 million, or $0.34 per basic and diluted common share"},{"label":"EPS","value":"$0.34 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}